![](https://endpts.com/wp-content/uploads/2017/08/epn-peer-review@x2.jpg)
Amy Burroughs to lead Cleave Therapeutics; Cynthia Collins clinches Editas CEO job amid historic CRISPR move
→ After bagging $12 million to advance its lead drug candidate CB-5339 — a (VCP)/p97 inhibitor — through early clinical development, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.